Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5906-5913

  Huang, Jian ^a   Hu, Jinyue ^c   Bian, Xiuwu ^d   Chen, Keqiang ^a   Gong, Wanghua ^b   Dunlop, Nancy M ^a   Howard, O M Zack ^a   Ji, Ming Wang ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c Central South University   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE RECEPTOR; RNA; TYROSINE;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSACTIVATION; TUMOR CELL;

BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FORMYL PEPTIDE; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

EID: 34250818797     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0691     Document Type: Article

References (46)

1. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol 2002;23:541-8.
2. Gao JL, Lee EJ, Murphy PM. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med 1999;189:657-62.
3. Rabiet MJ, Huet E, Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 2005;35:2486-95.
4. Xia SH, Hu LP, Hu H, et al. Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene 2002;21:6641-8.
5. Sun R, Iribarren P, Zhang N, et al. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J Immunol 2004;173:428-36.
6. Rescher U, Danielczyk A, Markoff A, Gerke V. Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells. J Immunol 2002;169:1500-4.
7. McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA, Perlmutter DH. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J Exp Med 1995;182:207-17.
8. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
9. Berens ME, Giese A. ". . .those left behind." Biology and oncology of invasive glioma cells. Neoplasia 1999;1:208-19.
10. Zhou Y, Bian X, Le Y, et al. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 2005;97:823-35.
11. Humphrey PA, Wong AJ, Vogelstein B, et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 1988;48:2231-8.
12. Bigner SH, Humphrey PA, Wong AJ, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-22.
13. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 2000;12:107-12.
14. Angers-Loustau A, Hering R, Werbowetski TE, Kaplan DR, Del Maestro RF. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2004;2:595-605.
15. Le Y, Hu J, Gong W, et al. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J Neuroimmunol 2000;111:102-8.
16. Le Y, Iribarren P, Zhou Y, et al. Silencing the formylpeptide receptor FPR by short-interfering RNA. Mol Pharmacol 2004;66:1022-8.
17. Mischel PS, Shai R, Shi T, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003;22:2361-73.
18. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87-98.
19. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986;149:9-14.
20. Layfield LJ, Willmore C, Tripp S, Jones C, Jensen RL. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol 2006;14:91-6.
21. Johns TG, Luwor RB, Murone C, et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci U S A 2003;100:15871-6.
22. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
23. Edwin F, Wiepz GJ, Singh R, et al. A historical perspective of the EGF receptor and related systems. Methods Mol Biol 2006;327:1-24.
24. Casas-Gonzalez P, Ruiz-Martinez A, Garcia-Sainz JA. Lysophosphatidic acid induces α1B-adrenergic receptor phosphorylation through Gβγ, phosphoinositide 3-kinase, protein kinase C and epidermal growth factor receptor transactivation. Biochim Biophys Acta 2003;1633:75-83.
25. Mori K, Kitayama J, Shida D, Yamashita H, Watanabe T, Nagawa H. Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. J Surg Res 2006;132:56-61.
26. Zhao Y, He D, Saatian B, et al. Regulation of lysophosphatidic acid-induced epidermal growth factor receptor transactivation and interleukin-8 secretion in human bronchial epithelial cells by protein kinase Cδ, Lyn kinase, and matrix metalloproteinases. J Biol Chem 2006;281:19501-11.
27. Vaingankar SM, Martins-Green M. Thrombin aivation of the 9E3/CEF4 chemokine involves tyrosine kinases including c-src and the epidermal growth factor receptor. J Biol Chem 1998;273:5226-34.
28. Neaud V, Duplantier JG, Mazzocco C, Kisiel W, Rosenbaum J. Thrombin up-regulates tissue factor pathway inhibitor-2 synthesis through a cyclooxygenase-2-dependent, epidermal growth factor receptor-independent mechanism. J Biol Chem 2004;279:5200-6.
29. Kanda Y, Mizuno K, Kuroki Y, Watanabe Y. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol 2001;132:1657-64.
30. Beaucage P, Moreau P. EGF receptor transactivation in angiotensin II and endothelin control of vascular protein synthesis in vivo. J Cardiovasc Pharmacol 2004;44 Suppl 1:S20-3.
31. Spinella F, Rosano L, Elia G, Di Castro V, Natali PG, Bagnato A. Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol 2004;44:S140-3.
32. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 1999;140:4659-68.
33. Kawanabe Y, Masaki T, Hashimoto N. Involvement of epidermal growth factor receptor-protein tyrosine kinase transactivation in endothelin-1-induced vascular contraction. J Neurosurg 2004;100:1066-71.
34. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60:5310-7.
35. Keely SJ, Uribe JM, Barrett KE. Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T84 cells. Implications for carbachol-stimulated chloride secretion. J Biol Chem 1998;273:27111-7.
36. Keely SJ, Calandrella SO, Barrett KE. Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular Ca(2+), PYK-2, and p60(src). J Biol Chem 2000;275:12619-25.
37. McCole DF, Keely SJ, Coffey RJ, Barrett KE. Transactivation of the epidermal growth factor receptor in colonic epithelial cells by carbachol requires extracellular release of transforming growth factor-α. J Biol Chem 2002;277:42603-12.
38. Newton JS. Angiotensin and epidermal growth factor receptor cross talk goes up and down. J Hypertens 2002;20:597-8.
39. Moriguchi Y, Matsubara H, Mori Y, et al. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-β synthesis via transcriptional and posttranscriptional mechanisms. Circ Res 1999;84:1073-84.
40. De Paolis P, Porcellini A, Savoia C, et al. Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens 2002;20:693-9.
41. Zachary I, Rozengurt E. Modulation of the epidermal growth factor receptor by mitogenic ligands: effects of bombesin and role of protein kinase C. Cancer Surv 1985;4:729-65.
42. Madarame J, Higashiyama S, Kiyota H, et al. Transactivation of epidermal growth factor receptor after heparin-binding epidermal growth factor-like growth factor shedding in the migration of prostate cancer cells promoted by bombesin. Prostate 2003;57:187-95.
43. Porcile C, Bajetto A, Barbieri F, et al. Stromal cell-derived factor-1α (SDF-1α/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 2005;308:241-53.
44. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-8.
45. Luttrell DK, Lee A, Lansing TJ, et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A 1994;91:83-7.
46. Tsai W, Morielli AD, Peralta EG. The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity. EMBO J 1997;16:4597-605.